A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate

Isr Med Assoc J. 2014 Oct;16(10):666.

Authors

M Galeazzi, L Bazzichi, G D Sebastiani, D Neri, E Garcia, N Ravenni, L Giovannoni, J Wilton, M Bardelli, C Baldi, E Selvi, A Iuliano, G Minisola, R Caporali, E Prisco, S Bombardieri

PMID: 25438467

No abstract available

Publication types

Clinical Trial, Phase I

MeSH terms

Antibodies
Antirheumatic Agents / administration & dosage
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / immunology
Arthritis, Rheumatoid / physiopathology
Dose-Response Relationship, Drug
Drug Delivery Systems
Drug Monitoring
Drug Therapy, Combination / methods
Fibronectins* / immunology
Fibronectins* / pharmacology
Humans
Immunologic Factors / immunology
Immunologic Factors / pharmacology
Injections, Subcutaneous
Interleukin-10* / immunology
Interleukin-10* / pharmacology
Maximum Tolerated Dose
Methotrexate / administration & dosage*
Pilot Projects

Substances

Antibodies
Antirheumatic Agents
Fibronectins
Immunologic Factors
extra domain A fibronectin, human
Interleukin-10
Methotrexate